News about 'diagnostics'

The Stop TB Partnership Working Group on New TB Vaccines (WGNV), Working Group on New TB Drugs (WGND), and New Diagnostics Working Group (NDWG) are developing an online course specifically designed for advocates and affected communities to provide a base of knowledge in TB research and to generate...

Click to access report. This is the eighteenth global report on tuberculosis (TB) published by WHO in a series that started in 1997. It provides a comprehensive and up-to-date assessment of the TB epidemic and progress in implementing and financing TB prevention, care and control at global, regional...

On September 5 and 6, 2012, the “Demystifying Pyrazinamide – Challenges and Opportunities” Workshop will be held at Johns Hopkins University and is sponsored by National Institute of Allergy and Infectious Diseases, Bill and Melinda Gates Foundation, Johns Hopkins University Center for AIDS...

TB REACH, an initiative of the Stop TB Partnership to promote early and increased TB case detection, today has launched its call for applications for Wave 3 funding. Partners of the Stop TB Partnership, national TB programmes, HIV programmes, local and international NGOs, civil society and...

Inaugural entrants showcase successful new approaches Thank you to all who submitted entries to the first InnovateTB contest. We are delighted to be able to help promote them as an ongoing effort of the InnovateTB Library. At the request of our stakeholders, we divided the winners into three...

The Stop TB Partnership made two exciting announcements today: 1. US$ 40 million committed to roll-out of Xpert The executive board of UNITAID today approved funding of US$ 30 million to scale up access to Xpert MTB/RIF, and reduce the cost of its use. In addition, the Stop TB Partnership’s TB...

World TB Day Congressional Briefing Tuberculosis – We Can Beat this Global Killer Wednesday, March 21, 2012 A briefing and update on tuberculosis (TB), a disease that is curable but still takes the lives of 4,000 people each day and is the number one killer of people living with HIV. Special areas...

The audience takes in the promise of the NC--002 trial. During the “Cure All: A briefing on the status of the most promising new TB drugs research” sponsored by the Critical Path to New TB Drug Regimens (CPTR) on Monday, March 19, Dr. Mel Spigelman, CEO & President, of TB Alliance announced the...

Click here for brochure. Vincent V, Rigouts L, Nduwamahoro E, Holmes B, Cunningham J, Guillerm M, Nathanson CM, Moussy F, De Jong B, Portaels F, Ramsay A. The TDR Tuberculosis Strain Bank: a resource for basic science, tool development and diagnostic services. Int J Tuberc Lung Dis. 2012 Jan;16(1):...

Click here for full report. Today, the fourth annual G-FINDER survey tracking funding for research and development of neglected disease technologies was released. This year’s report shows that funding for product development is on the decline and product development partnerships (PDPs) have been...

Click here for full report Source: Stop TB Partnership News, November 3, 2011 A plan targeting researchers around the world and providing them with a framework to achieve the research objectives of the the Global Plan to Stop TB 2011-2015 and beyond, towards elimination of TB, was launched on...

Special Focus: Neglected Diseases [PART 1]. Future Medicinal Chemistry. August 2011, Volume 3, Number 10 ( free issue ) Special Focus: Neglected Diseases [PART 2]. Future Medicinal Chemistry. September 2011, Volume 3, Number 11 (not yet released) The August and September issues of Future Medicinal...

A Dowsett, Health Protection Agency/Science Photo Library Vento S, Lanzafame M. Tuberculosis and cancer: a complex and dangerous liaison. Lancet Oncol. 2011 Jun;12(6):520-2. This week we review a commentary on the correlations between tuberculosis and cancer, specifically lung cancer. There are...

Louw GE, Warren RM, Gey van Pittius NC, Leon R, Jimenez A, Pando RH, McEvoy CR, Grobbelaar M, Murray M, van Helden PD, Victor TC. Rifampicin Reduces Susceptibility to Ofloxacin in Rifampicin Resistant Mycobacterium tuberculosis through Efflux. Am J Respir Crit Care Med. 2011 Apr 21. [Epub ahead of...

MIchael D. Iseman Dr. Michael D. Iseman, a world renowned pulmonologist and leading expert on tuberculosis has joined Oxford Immunotec as the Senior Scientific Advisor. To read full story, click here . In May 2010, the WGND had the honor of interviewing Dr. Iseman in our “Voices from the Fight to...